TAVNEOS Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Tavneos, and when can generic versions of Tavneos launch?
Tavneos is a drug marketed by Chemocentryx and is included in one NDA. There are four patents protecting this drug.
This drug has one hundred and eight patent family members in thirty-seven countries.
The generic ingredient in TAVNEOS is avacopan. One supplier is listed for this compound. Additional details are available on the avacopan profile page.
DrugPatentWatch® Generic Entry Outlook for Tavneos
Tavneos will be eligible for patent challenges on October 7, 2025. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be February 3, 2031. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for TAVNEOS?
- What are the global sales for TAVNEOS?
- What is Average Wholesale Price for TAVNEOS?
Summary for TAVNEOS
| International Patents: | 108 |
| US Patents: | 4 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 27 |
| Patent Applications: | 86 |
| Drug Prices: | Drug price information for TAVNEOS |
| What excipients (inactive ingredients) are in TAVNEOS? | TAVNEOS excipients list |
| DailyMed Link: | TAVNEOS at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for TAVNEOS
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for TAVNEOS
| Drug Class | Complement 5a Receptor Antagonist |
| Mechanism of Action | Complement 5a Receptor Antagonists Cytochrome P450 3A4 Inhibitors |
US Patents and Regulatory Information for TAVNEOS
TAVNEOS is protected by four US patents and two FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of TAVNEOS is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting TAVNEOS
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: AN ADJUNCTIVE TREATMENT OF ADULT PATIENTS WITH TAVNEOS (AVACOPAN) WITH SEVERE ACTIVE ANCA-ASSOCIATED VASCULITIS (GPA AND MPA) IN COMBINATION WITH STANDARD THERAPY INCLUDING GLUCOCORTICOIDS
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
C5aR antagonists
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
C5aR antagonists
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
FDA Regulatory Exclusivity protecting TAVNEOS
AS AN ADJUNCTIVE TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE ANTI-NEUTROPHIL CYTOPLASMIC AUTOANTIBODY (ANCA)-ASSOCIATED VASCULITIS (GRANULOMATOSIS WITH POLYANGIITIS [GPA] AND MICROSCOPIC POLYANGIITIS [MPA])
Exclusivity Expiration: ⤷ Sign Up
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chemocentryx | TAVNEOS | avacopan | CAPSULE;ORAL | 214487-001 | Oct 7, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Chemocentryx | TAVNEOS | avacopan | CAPSULE;ORAL | 214487-001 | Oct 7, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Chemocentryx | TAVNEOS | avacopan | CAPSULE;ORAL | 214487-001 | Oct 7, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Chemocentryx | TAVNEOS | avacopan | CAPSULE;ORAL | 214487-001 | Oct 7, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for TAVNEOS
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Vifor Fresenius Medical Care Renal Pharma France | Tavneos | avacopan | EMEA/H/C/005523 Tavneos, in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA). |
Authorised | no | no | yes | 2022-01-11 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for TAVNEOS
When does loss-of-exclusivity occur for TAVNEOS?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Argentina
Patent: 7162
Patent: C5AR ANTAGONISTAS
Estimated Expiration: ⤷ Sign Up
Australia
Patent: 09330194
Patent: C5aR antagonists
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 0923384
Patent: composto, composição farmacêutica, e, métodos para tratar um mamífero, e para inibir quimiotaxia celular
Estimated Expiration: ⤷ Sign Up
Patent: 2012033075
Patent: composto piperidina substituído antagonista de receptor c5a, composição farmacêutica, e, uso do composto.
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 47522
Patent: ANTAGONISTES DE C5AR (C5AR ANTAGONISTS)
Estimated Expiration: ⤷ Sign Up
Patent: 65223
Patent: ANTAGONISTES DE C5AR (C5AR ANTAGONISTS)
Estimated Expiration: ⤷ Sign Up
China
Patent: 2264227
Estimated Expiration: ⤷ Sign Up
Patent: 3068385
Patent: C5ar antagonists
Estimated Expiration: ⤷ Sign Up
Colombia
Patent: 00172
Patent: C5AR ANTAGONISTAS
Estimated Expiration: ⤷ Sign Up
Croatia
Patent: 0161010
Estimated Expiration: ⤷ Sign Up
Patent: 0171176
Estimated Expiration: ⤷ Sign Up
Cyprus
Patent: 25130
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 81778
Estimated Expiration: ⤷ Sign Up
Patent: 85064
Estimated Expiration: ⤷ Sign Up
Patent: 78658
Estimated Expiration: ⤷ Sign Up
Eurasian Patent Organization
Patent: 0874
Patent: АНТАГОНИСТЫ C5aR (C5aR ANTAGONISTS)
Estimated Expiration: ⤷ Sign Up
Patent: 1101009
Patent: АНТАГОНИСТЫ C5aR
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 81778
Patent: ANTAGONISTES DE C5AR (C5AR ANTAGONISTS)
Estimated Expiration: ⤷ Sign Up
Patent: 85064
Patent: ANTAGONISTES DE C5AR (C5AR ANTAGONISTS)
Estimated Expiration: ⤷ Sign Up
Patent: 78658
Patent: ANTAGONISTES DE C5AR (C5AR ANTAGONISTS)
Estimated Expiration: ⤷ Sign Up
Patent: 08477
Patent: ANTAGONISTES DU C5AR (C5AR ANTAGONISTS)
Estimated Expiration: ⤷ Sign Up
Patent: 15504
Patent: ANTAGONISTES DU C5AR (C5AR ANTAGONISTS)
Estimated Expiration: ⤷ Sign Up
France
Patent: C1020
Estimated Expiration: ⤷ Sign Up
Hong Kong
Patent: 64639
Patent: 拮抗劑 (C5AR ANTAGONISTS C5AR)
Estimated Expiration: ⤷ Sign Up
Hungary
Patent: 30630
Estimated Expiration: ⤷ Sign Up
Patent: 33644
Estimated Expiration: ⤷ Sign Up
Patent: 200025
Estimated Expiration: ⤷ Sign Up
Israel
Patent: 3676
Patent: אנטגוניסטים של ra5c (C5ar antagonists)
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 19730
Estimated Expiration: ⤷ Sign Up
Patent: 89989
Estimated Expiration: ⤷ Sign Up
Patent: 38086
Estimated Expiration: ⤷ Sign Up
Patent: 12513402
Estimated Expiration: ⤷ Sign Up
Patent: 13529647
Estimated Expiration: ⤷ Sign Up
Patent: 16130249
Patent: Ｃ５ａＲアンタゴニスト (C5AR ANTAGONISTS)
Estimated Expiration: ⤷ Sign Up
Patent: 17193586
Patent: Ｃ５ａＲアンタゴニスト (C5AR ANTAGONISTS)
Estimated Expiration: ⤷ Sign Up
Jordan
Patent: 46
Patent: مواد مضادة C5aR (C5aR Antagonists)
Estimated Expiration: ⤷ Sign Up
Lithuania
Patent: 2022006
Estimated Expiration: ⤷ Sign Up
Patent: 08477
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 11006550
Patent: C5AR ANTAGONISTAS. (C5AR ANTAGONISTS.)
Estimated Expiration: ⤷ Sign Up
Morocco
Patent: 975
Patent: مضادات c5ar
Estimated Expiration: ⤷ Sign Up
Netherlands
Patent: 1166
Estimated Expiration: ⤷ Sign Up
New Zealand
Patent: 4140
Patent: C5AR ANTAGONISTS
Estimated Expiration: ⤷ Sign Up
Norway
Patent: 22018
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 81778
Estimated Expiration: ⤷ Sign Up
Patent: 85064
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 81778
Estimated Expiration: ⤷ Sign Up
Patent: 85064
Estimated Expiration: ⤷ Sign Up
Patent: 78658
Estimated Expiration: ⤷ Sign Up
Serbia
Patent: 998
Patent: ANTAGONISTI C5AR (C5AR ANTAGONISTS)
Estimated Expiration: ⤷ Sign Up
Patent: 332
Patent: ANTAGONISTI C5AR (C5AR ANTAGONISTS)
Estimated Expiration: ⤷ Sign Up
Singapore
Patent: 2338
Patent: C5AR ANTAGONISTS
Estimated Expiration: ⤷ Sign Up
Slovenia
Patent: 81778
Estimated Expiration: ⤷ Sign Up
Patent: 85064
Estimated Expiration: ⤷ Sign Up
South Africa
Patent: 1104588
Patent: C5AR ANTAGONISTS
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 1680818
Estimated Expiration: ⤷ Sign Up
Patent: 110100661
Patent: C5AR ANTAGONISTS
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 77548
Estimated Expiration: ⤷ Sign Up
Patent: 32975
Estimated Expiration: ⤷ Sign Up
Patent: 34746
Estimated Expiration: ⤷ Sign Up
Taiwan
Patent: 65434
Estimated Expiration: ⤷ Sign Up
Patent: 1028380
Patent: C5aR antagonists
Estimated Expiration: ⤷ Sign Up
Ukraine
Patent: 2514
Patent: АНТАГОНІСТИ C5aR
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering TAVNEOS around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Serbia | 54998 | ANTAGONISTI C5AR (C5AR ANTAGONISTS) | ⤷ Sign Up |
| World Intellectual Property Organization (WIPO) | 2020112961 | ⤷ Sign Up | |
| Brazil | 112022007489 | FORMA AMORFA DE UM RECEPTOR C5A DE COMPONENTE DO COMPLEMENTO | ⤷ Sign Up |
| Hungary | E062551 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for TAVNEOS
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 3508477 | PA2022006 | Lithuania | ⤷ Sign Up | PRODUCT NAME: AVAKOPANAS IR JO FARMACINIU POZIURIU PRIIMTINOS DRUSKOS ; REGISTRATION NO/DATE: EU/1/21/1605 20220111 |
| 2381778 | 17/2022 | Austria | ⤷ Sign Up | PRODUCT NAME: AVACOPAN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES; REGISTRATION NO/DATE: EU/1/21/1605 (MITTEILUNG) 20220119 |
| 2381778 | CA 2022 00022 | Denmark | ⤷ Sign Up | PRODUCT NAME: AVACOPAN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REG. NO/DATE: EU/1/21/1605 20220119 |
| 2381778 | 122022000029 | Germany | ⤷ Sign Up | PRODUCT NAME: AVACOPAN; REGISTRATION NO/DATE: EU/1/21/1605 20220111 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
